Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · TATVA

TATVA

CommoditiesChemicals & Petrochemicals₹3853 cr market cap
₹1637.20 ▼ -0.71% today As of 19 Nov 2026
52-week low ₹1052.4052-week high ₹1991.20

-17.2% from the 52-week high · +56.7% above the low

Tatva Chintan Pharma Chem Ltd. is a chemicals manufacturing company. The company is headquartered in Vadodara, Gujarat and currently employs 608 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in the manufacturing of verity of chemicals include structure directing agents (SDAs), phase transfer catalysts (PTCs), electrolyte salts for capacitor batteries, and pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC). Its SDAs are quarternary salts, which helps in the formation of channels and pores during the synthesis of zeolites. Its PTCs are used to facilitate the migration of a reactant from one phase into another phase where the reaction occurs in a heterogeneous multi-phase system. The firm operates two manufacturing facilities situated at Ankleshwar and Dahej in Bharuch, Gujarat, India. The firm is focused on serving various customers across various industries, including the automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavors and fragrances industries.

The short version. TATVA reported revenue of ₹217 crore for Sep 2026, up 75.0% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Return on equity was 5.4% in Mar 2026. Promoter holding was 72.02% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

TATVA trades 17.2% below its 52-week high and 56.7% above its 52-week low.

Change over period: —

1M-13.4%
3M+0.1%
6M+32.8%
1Y+5.8%

2 · The business

Is it growing?

Sales, year on year+75.0%

Sep 2026 revenue of ₹217 cr.

Profit, year on year+110.0%

Sep 2026 net profit of ₹21 cr.

Net margin9.9%

1.9 pts higher than a year earlier.

3-year growth-2.6% profit

Revenue compounded at 5.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue21716713413112411710886
Net profit2116101510710
Net margin %9.99.67.711.58.05.71.00.2
EPS (₹)9.176.834.416.484.242.840.440.06

Annual

FY2026FY2025FY2024FY2023FY2022
Revenue506383394424434
Net profit426304596
Net margin %8.31.57.710.722.1
EPS (₹)17.982.4412.9820.5243.25

3 · The quality

How well does it turn capital into profit?

Return on equity was 5.4% in Mar 2026; debt to equity is 0.15.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %5.40.84.18.8
Return on capital %7.61.26.810.2
EBITDA margin %19.09.518.914.6
Net margin %8.31.57.610.6

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR5.9%—
Profit CAGR-2.6%—
Debt to equity0.15
Interest cover21.0x
Current ratio1.64
P/E ratio61.4

4 · The owners

Who holds it, and are they adding?

Promoter holding72.02%

Unchanged over 8 quarters.

Foreign institutions4.38%

Up 1.02 pts over 8 quarters.

Domestic institutions3.21%

Down 3.13 pts over 8 quarters.

Mutual fund schemes9

+5 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter72.0272.0272.0272.0272.0272.0272.0272.020.0
FII3.363.33.263.394.173.823.934.38+1.02
DII6.345.465.113.863.332.993.113.21-3.13
Public18.2819.2219.620.7320.4821.1720.9420.39+2.11

Mutual fund holdings · Oct 2026

9 schemes hold this stock

4 the month before.

  • JM Multi Asset Allocation Fund1.09% of NAV
  • ICICI Prudential MNC Fund0.67% of NAV
  • Nippon India ELSS Tax Saver Fund0.61% of NAV
  • WhiteOak Capital Pharma and Healthcare Fund0.37% of NAV
  • ICICI Prudential Commodities Fund0.24% of NAV
  • Mahindra Manulife Small Cap Fund0.08% of NAV
  • Motilal Oswal BSE 1000 Index Fund0.01% of NAV
  • ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.01% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for TATVA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about TATVA

What is the TATVA share price?

TATVA (TATVA) last closed at ₹1,637.20, down 0.71% on the day. Its 52-week range is ₹1,052.40 to ₹1,991.20.

What is the market cap of TATVA?

TATVA has a market capitalisation of about ₹3,853 crore. Its price-to-earnings ratio is 61.4.

How are TATVA's latest results?

TATVA reported revenue of ₹217 crore for Sep 2026, up 75.0% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Return on equity was 5.4% in Mar 2026. Promoter holding was 72.02% in Sep 2026, up 0.00 points over 8 quarters.

Who owns TATVA?

As of Sep 2026, shareholding was: Promoter 72.02%, FII 4.38%, DII 3.21%, Public 20.39%.

How many mutual funds hold TATVA?

9 mutual fund schemes held TATVA in October 2026. That compares with 4 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Sep 2025 · Final Dividend - Rs. 1
  • 06 Sep 2024 · Final Dividend - Rs. 2
  • 08 Sep 2023 · Final Dividend - Rs. 2
  • 08 Sep 2022 · Final Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.